Krayzie Bone the Method Is Proven Effective Again and Again

U.S. markets open in 1 hour 32 minutes

S&P Futures
Dow Futures
Nasdaq Futures
Russell 2000 Futures
Crude Oil
Gold
Silver
EUR/USD
10-Yr Bond
Vix
GBP/USD
USD/JPY
BTC-USD
CMC Crypto 200
FTSE 100
Nikkei 225

WEF 2022:

Yahoo Finance is in Davos! Get the latest updates here

FDA Grants PMA for the AccelStim Bone Growth Stimulation Device — Expanding Orthofix's Portfolio of Market-Leading Bone Healing Therapy Solutions

LEWISVILLE, Texas, May 04, 2022--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the U.S. Food and Drug Administration (FDA) pre-market approval for the AccelStim^™ bone healing therapy Class III device. The AccelStim device provides a safe and effective nonsurgical treatment for indicated fresh fractures and for fractures that have not healed (nonunions). The device generates a Low-Intensity Pulsed Ultrasound (LIPUS) signal to stimulate the bone's natural healing process to promote fracture healing. Commercial availability of the AccelStim device is anticipated to occur in the second quarter of this year through a targeted and phased launch plan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005443/en/

The Orthofix AccelStim™ bone healing therapy device is indicated for fresh fractures and fractures that have not healed. The device generates a Low-Intensity Pulsed Ultrasound (LIPUS) signal to stimulate the bone's natural healing process to promote fracture healing. (Photo: Business Wire)

"As the market leader in bone growth stimulation devices, more than a million patients have been treated with our Pulsed Electromagnetic Field Stimulation (PEMF) systems," said Orthofix President of Global Spine Kevin Kenny. "With the addition of the AccelStim device, Orthofix is now the first and only company to offer both PEMF and LIPUS bone growth stimulation devices, and one of only two companies in the U.S. with a fresh fracture indication. We believe that expanding access to patients should help grow the existing $100M market for fresh fracture LIPUS solutions. This investment and approval further demonstrates our leadership in and commitment to the bone growth stimulation market."

The AccelStim device is worn externally in the region of the fracture, typically for 20 minutes daily. Treatment length may vary and is determined by the prescribing physician on an individual basis according to the fracture healing progress. The device is lightweight, adjustable and portable, and includes a rechargeable battery that allows freedom of movement during treatment. The AccelStim system includes a treatment calendar to engage patients in their recovery. The LIPUS technology stimulates bone healing at the molecular, cellular and tissue level and has been proven to accelerate fracture-healing recovery by 38 percent for indicated fresh fractures and an overall clinical success rate of 86 percent for nonunion fractures.

Since 1986, Orthofix Bone Growth Therapy has helped promote the natural bone-healing process in patients. The AccelStim device with LIPUS technology complements the Orthofix portfolio of PEMF bone growth stimulation devices which consists of the CervicalStim^™, SpinalStim^™ and PhysioStim^™ systems. With the addition of the AccelStim device, Orthofix now provides the most treatment indications in the bone growth stimulation market.

About Orthofix

Orthofix Medical Inc. is a global medical device company with a spine and orthopedics focus. The Company's mission is to deliver innovative, quality-driven solutions while partnering with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, Orthofix's spine and orthopedics products are distributed in more than 60 countries via the Company's sales representatives and distributors. For more information, please visit Orthofix.com.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, relating to our business and financial outlook, which are based on our current beliefs, assumptions, expectations, estimates, forecasts and projections. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "projects," "intends," "predicts," "potential," or "continue" or other comparable terminology. These forward-looking statements are not guarantees of our future performance and involve risks, uncertainties, estimates and assumptions that are difficult to predict, including the risks described in Part I, Item 1A under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K"). In addition to the risks described there, factors that could cause or contribute to such differences may include, but are not limited to: the risk that surgeons may be slow to adopt the AccelStim device; the risk that future patient studies or clinical experience and data may indicate that treatment with the AccelStim device does not improve patient outcomes as much as previously believed, or otherwise call into question the benefits of its use to patients, hospitals and surgeons; the risk that the product may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that insurance payers may decline to reimburse healthcare providers for the use of our products.

This list of risks, uncertainties and other factors is not complete. We discuss some of these matters more fully, as well as certain risk factors that could affect our business, financial condition, results of operations, and prospects, in reports we file from time-to-time with the SEC, which are available to read at. Any or all forward-looking statements that we make may turn out to be wrong (due to inaccurate assumptions that we make or otherwise), and our actual outcomes and results may differ materially from those expressed in these forward-looking statements. You should not place undue reliance on any of these forward-looking statements. Further, any forward-looking statement speaks only as of the date hereof, unless it is specifically otherwise stated to be made as of a different date. We undertake no obligation to update, and expressly disclaim any duty to update, our forward-looking statements, whether as a result of circumstances or events that arise after the date hereof, new information, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005443/en/

Contacts

Alexa Huerta
Investor Relations
Tel 214 937 3190
alexahuerta@orthofix.com

Denise Landry
Media Relations
Tel 214 937 2529
deniselandry@orthofix.com

Monkeypox cases are driving up stock prices for these companies

Growing concern about the emergence of monkeypox in Europe and the U.S. has sent shares of several vaccine and drug companies soaring. At least three cases have been confirmed in the U.S. over the past year, including one in an adult male who recently traveled from Canada to Massachusetts. Several companies that have developed smallpox vaccines or therapeutics have seen their shares prices jump, and some of those drug makers may be familiar to investors who paid close attention to stocks that got a boost in early 2020 after China first disclosed the outbreak of the new coronavirus in Wuhan that was eventually identified as SARS-CoV-2.
AdCharacters That Stunned Fans After Being Replaced

When a TV show decides to replace an actor, the fans are usually not too happy. Here's our list of 10 most shocking cast replacements
Dexcom Is in Talks to Acquire Device Firm Insulet

(Bloomberg) -- Dexcom Inc. is in talks to acquire medical-device company Insulet Corp. in a deal that would create a giant in diabetes devices, according to people with knowledge of the matter. Insulet rose as much as 16% in after-market trading on the news. Most Read from BloombergBroadcom in Talks to Acquire Cloud Company VMwareStocks Climb in Risk-On Day While Bonds Decline: Markets WrapBiden's Latest Taiwan Gaffe Stokes Tensions With BeijingBiden Misspeaks on Taiwan, Says US Military Would I
Top Virus Expert Warns "Very Strongly" That You Do This Now, Vaccinated or Not

We're certainly come a long way since the COVID pandemic first began in 2020. With the help of precautionary measures and major scientific developments, the U.S. has been able to fight the coronavirus over the last two years and bring numbers down significantly. As a result, restrictions like mask mandates and vaccine requirements have been lifted, signaling a different phase of the pandemic. Unfortunately, that may have been wishful thinking, as the crisis is far from over. In fact, both infect
AdBeautiful Women are Waiting

Meet Chat Partners & Date Live. Find Beautiful Women Today. Chat Now!
SpringWorks shares jump 14%; company plans to seek FDA approval for desmoid tumor therapy this year

Shares of SpringWorks Therapeutics Inc. were up 14.9% in premarket trading on Tuesday after the company said a late-stage clinical trial evaluating its treatment for patients with progressing desmoid tumors met its primary endpoint. A desmoid tumor is a rare disease. The double-blind, placebo-controlled Phase 3 trial testing nirogacestat improved progression-free survival compared with placebo. It also met all secondary endpoints. SpringWorks said it plans to submit an application for nirogacest
AdBoy Reels In Purse From Lake, Realizes It's...

Boy Fishes Old Purse And Is Staggered When He Discovers What The Bag Contains
Ocugen shares jump premarket after FDA lifts clinical hold on trial of COVID-19 vaccine candidate

Ocugen Inc. shares jumped 9% premarket Monday, after the biotech said the Food and Drug Administration has lifted its clinical hold on Ocugen's Phase 2/3 trial of its COVID-19 vaccine candidate Covaxin. "We're extremely pleased that we can proceed with our clinical trials for COVAXIN(TM), our whole virus inactivated COVID-19 vaccine candidate. The need for delivering an additional, differentiated vaccine option, we believe, remains a priority," said Dr. Shankar Musunuri, CEO and co-founder of Oc
AdThe Most Talented Rock Bands In History, Ranked

Prepare yourself to a ride of nostalgia, as we review some of the bestAmerican bands of all time
How Does Jif Peanut Butter Get Salmonella, Anyway?

The J.M. Smucker Co.—maker of Jif peanut butter, Uncrustables, and many other popular products—recently recalled multiple peanut butters after several people became ill from salmonella, TODAY explains. But how is peanut butter at risk for salmonella bacteria in the first place?
Could an HIV Vaccine Be Available Soon?

Epidemiologist Dr. Perry Halkitis shares that the HIV vaccine is very promising and he thinks in the near future it might be available. Dr. Perry shares that the vaccine will not help people who are living with it, but it will hopefully help people from ever getting HIV in the first place. The Stigma of HIV Still at Play in Blood Donation?
AdIt's Hard To Believe These Planes Are Real

The 20 Most Unnecessary Planes Of All Time
Monkeypox Cases Are Spreading; Here's What You Need to Know

Several confirmed cases of monkeypox have been found in a few European countries (Spain, Italy, Portugal, and Sweden), Canada, the UK, and now the US - in Massachusetts and Florida. If you've never heard of monkeypox before, it's because it's a very rare disease found primarily in remote parts of central and western Africa.
Cancer Survivor Rita Wilson Says She Stopped Eating This After Her Diagnosis

An actor and producer turned country music star—not to mention the wife of Oscar winner and Hollywood darling Tom Hanks—Rita Wilson has kept extraordinarily busy in the world of entertainment. But in 2015, all of that came to a standstill when the star was diagnosed with breast cancer. Taking leave from starring in a Broadway play to begin her treatment, Wilson underwent a bilateral mastectomy, which proved successful in keeping her cancer at bay. Today, Wilson is enjoying good health, and says

forbeswouesed.blogspot.com

Source: https://finance.yahoo.com/news/fda-grants-pma-accelstim-bone-110000253.html

Krayzie Bone the Method Is Proven Effective Again and Again

S&P Futures

Dow Futures

Nasdaq Futures

Russell 2000 Futures

Crude Oil

Gold

Silver

EUR/USD

10-Yr Bond

Vix

GBP/USD

USD/JPY

BTC-USD

CMC Crypto 200

FTSE 100

Nikkei 225

Yahoo Finance is in Davos! Get the latest updates here

FDA Grants PMA for the AccelStim Bone Growth Stimulation Device — Expanding Orthofix's Portfolio of Market-Leading Bone Healing Therapy Solutions

Monkeypox cases are driving up stock prices for these companies

AdCharacters That Stunned Fans After Being Replaced

Dexcom Is in Talks to Acquire Device Firm Insulet

Top Virus Expert Warns "Very Strongly" That You Do This Now, Vaccinated or Not

AdBeautiful Women are Waiting

SpringWorks shares jump 14%; company plans to seek FDA approval for desmoid tumor therapy this year

AdBoy Reels In Purse From Lake, Realizes It's...

Ocugen shares jump premarket after FDA lifts clinical hold on trial of COVID-19 vaccine candidate

AdThe Most Talented Rock Bands In History, Ranked

How Does Jif Peanut Butter Get Salmonella, Anyway?

Could an HIV Vaccine Be Available Soon?

AdIt's Hard To Believe These Planes Are Real

Monkeypox Cases Are Spreading; Here's What You Need to Know

Cancer Survivor Rita Wilson Says She Stopped Eating This After Her Diagnosis

0 Response to "Krayzie Bone the Method Is Proven Effective Again and Again"

Postar um comentário

Iklan Atas Artikel

Iklan Tengah Artikel 1

Iklan Tengah Artikel 2

Iklan Bawah Artikel